Extracellular Vesicles from Human Amniotic Fluid Stem Cells for Treatment of Kidney Diseases
A subset of amniotic fluid stem cells (AFSCs) secrete extracellular vesicles (EVs) that can modulate glomerular signaling
More than 31M people suffer from Chronic Kidney Disease in the US, and the cost borne by the healthcare system is around $70K per patient annually.
A subset of amniotic fluid stem cells (AFSCs) secrete extracellular vesicles (EVs) that can modulate glomerular signaling. Specific proteins and micro-RNAs (miRs) within EVs have been identified that modulate signaling (e.g., via VEGF), and may have a protective role in various diseases. Such EVs have shown therapeutic effect following single dose administration in slowing renal disease in an Alport disease mouse model (, & ).
- Nature 2017 https://doi.org/10.1038/s41598-017-17061-2
- EVs are non-immunogenic permitting allogeneic use
- EVs are stable in vivo
- EVs (and/or their constituents) can be packaged in an off-the-shelf product, unlike stem cells
- Certain EV constituents may also be used as biomarkers in kidney disease
- Targeted therapy designed to preserve renal function
- Wide applicability across an array of renal diseases
CHLA Case No. 2015-016
- Patent application submitted
- Development partner